Edgewise Therapeutics (EWTX), on Thursday, announced that it will host a live webcast on Wednesday, April 2, 2025, at 8:30 AM ET to discuss the top-line results from its Phase 2 CIRRUS-HCM 28-day trial of EDG-7500 in patients with hypertrophic cardiomyopathy or HCM.
HCM, the leading cause of sudden cardiac death in young people, is a hereditary heart condition characterized by the thickening of the heart muscle, making it harder for the heart to pump blood effectively. Some of the common symptoms of HCM include breathlessness, irregular heartbeats, chest pain, tiredness, dizziness, or even fainting.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.